文献速递细菌感染、耐药与抗菌药物

SC5005通过耗散膜电位杀灭金黄色葡萄球菌持留菌且未检测到耐药性

SC5005 dissipates the membrane potential to kill Staphylococcus aureus persisters without detectable resistance.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该研究评估了索拉非尼衍生物SC5005对金黄色葡萄球菌的耐药倾向、作用机制及抗持留菌活性。SC5005通过去极化和渗透细菌细胞质膜、降低ATP产生而杀菌,连续200代亚致死浓度暴露未观察到耐药性,且对哺乳动物细胞膜无显著影响;相比其他杀菌抗生素,SC5005在清除浮游和生物膜内持留菌方面表现更优。

要点

  • SC5005通过破坏细菌细胞膜电位和通透性、降低ATP发挥杀菌作用。
  • 连续200代亚致死浓度暴露未观察到金黄色葡萄球菌对SC5005产生耐药性。
  • SC5005清除浮游及生物膜内持留菌的活性优于其他杀菌抗生素。

核心结论

  • SC5005因低耐药倾向和强效持留菌清除活性,是开发针对金黄色葡萄球菌生物膜相关感染新疗法的有前景的先导化合物。

研究设计与样本

  • 通过评估自发耐药和多代选择实验分析金黄色葡萄球菌对SC5005的耐药倾向。
  • 采用大分子合成、LIVE/DEAD、ATPlite和DiOC2(3)染色研究SC5005的作用机制。
  • 使用溶血和乳酸脱氢酶(LDH)实验及流式细胞术检测SC5005对哺乳动物细胞质膜的影响。

主要发现

  • SC5005使细菌细胞质膜去极化和渗透,导致ATP产生减少。
  • 连续200代暴露于亚致死浓度SC5005后,未观察到金黄色葡萄球菌产生耐药性。
  • SC5005的膜扰动活性对细菌具有特异性,未检测到显著溶血或人HT-29细胞LDH释放。
  • 与其他杀菌抗生素相比,SC5005在清除浮游和生物膜内金黄色葡萄球菌持留菌方面表现出更优活性。

临床怎么用

  • SC5005可作为开发针对金黄色葡萄球菌生物膜相关感染新疗法的先导化合物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In the past few decades, multiple-antibiotic-resistant Staphylococcus aureus has emerged and quickly spread in hospitals and communities worldwide. Additionally, the formation of antibiotic-tolerant persisters and biofilms further reduces treatment efficacy. Previously, we identified a sorafenib derivative, SC5005, with bactericidal activity against MRSA in vitro and in vivo. Here, we sought to elucidate the resistance status, mode of action and anti-persister activity of this compound. METHODS: The propensity of S. aureus to develop SC5005 resistance was evaluated by assessment of spontaneous resistance and by multi-passage selection. The mode of action of SC5005 was investigated using macromolecular synthesis, LIVE/DEAD and ATPlite assays and DiOC2(3) staining. The effect of SC5005 on the mammalian cytoplasmic membrane was measured using haemolytic and lactate dehydrogenase (LDH) assays and flow cytometry. RESULTS: SC5005 depolarized and permeabilized the bacterial cytoplasmic membrane, leading to reduced ATP production. Because of this mode of action, no resistance of S. aureus to SC5005 was observed after constant exposure to sub-lethal concentrations for 200 passages. The membrane-perturbing activity of SC5005 was specific to bacteria, as no significant haemolysis or release of LDH from human HT-29 cells was detected. Additionally, compared with other bactericidal antibiotics, SC5005 exhibited superior activity in eradicating both planktonic and biofilm-embedded S. aureus persisters. CONCLUSIONS: Because of its low propensity for resistance development and potent persister-eradicating activity, SC5005 is a promising lead compound for developing new therapies for biofilm-related infections caused by S. aureus.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Lu CH, Shiau CW, Chang YC, et al. SC5005 dissipates the membrane potential to kill Staphylococcus aureus persisters without detectable resistance. J Antimicrob Chemother. 2021. PMID: 33855344. doi:10.1093/jac/dkab114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。